You Might Also Like
Also By This Author
“It’s a significant finding because it’s repeated,” says Simon Helfgott, MD, an associate professor of medicine in the Division of Rheumatology, Immunology and Allergy at Harvard Medical School, Boston, and a past physician editor of The Rheumatologist. Dr. Helfgott has written about work–life balance issues in the field. “[This result] tells us that we have done something right in rheumatology in that we have been able to blend an interesting, intellectually stimulating profession and practice with the ability to help people,” he says.
Anne Bass, MD, past chair of the ACR’s Committee on Rheumatology Training and Workforce Issues and rheumatology fellowship program director for the Hospital for Special Surgery, New York, put it even more succinctly, “You don’t go into rheumatology to make a lot of money. You do it because you’re interested in it.”
Advances in Patient Care
But Drs. Bass and Helfgott don’t see the field’s finances as a factor in the happiness ranking. Both point toward the field’s decades-long progression in treatment options. Years ago, rheumatologists had little in their toolbox to offer patients: aspirin, steroids and gold. Now, prescribing patients TNF inhibitors and other biologics is included in standard treatment plans.
“I’ll date myself, but when I was a fellow, we would kind of reserve methotrexate for the most severe cases of rheumatoid arthritis (RA), and it was almost like you didn’t want to use it too early because if it didn’t work, there wasn’t much else you could do for the patient,” Dr. Helfgott says. “And now we use methotrexate as the start of the line for your patient with RA and other diseases.”
“Looking at my own career and my own experience, it’s so much more satisfying to make people better,” Dr. Bass says. “That’s why we became doctors.”
Dr. Bass says she’s even more hopeful scientific breakthroughs will continue to occur in the coming years and will further bolster rheumatologists’ options for treating diseases, such as scleroderma and system lupus erythematosus (SLE). “Having lots of choices, knowing that every year there will be new options available, and having much more of an optimistic view … is huge,” she says.